Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy-Reference-Cited by-同舟云学术

Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy

Published:2013-01-08 Issue:1 Volume:14 Page:14-19
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Negri F V,Musolino A,Naldi N,Bortesi B,Missale G,Laccabue D,Zerbini A,Camisa R,Chernyschova N,Bisagni G,Loupakis F,Ruzzo A,Neri T M,Ardizzoni A

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/tpj201254.pdf

Reference39 articles.

1. Laskin JJ, Sandler AB . Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 2004; 30: 1–17.

2. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803–1810.

3. Hecht JR, Mitchell E, Neubauer MA, Burris HA, Swanson P, Lopez T et al. Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 2010; 16: 2205–2213.

4. Iannello A, Ahmad A . Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 2005; 24: 487–499.

5. Fanger MW, Shen L, Graziano RF, Guyre PM . Cytotoxicity mediated by human Fc receptors for IgG. Immunol Today 1989; 10: 92–99.

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NK Cytotoxicity Mediated by NK-92 Cell Lines Expressing Combinations of Two Allelic Variants for FCGR3;Antibodies;2024-07-12

2. Análisis del polimorfismo FcƴRIII en pacientes con cáncer de mama HER2+ en tratamiento neoadyuvante con Quimioterapia más trastuzumab y pertuzumab;Oncología Clínica;2023-09-18

3. Pharmacogenetics Role of Genetic Variants in Immune-Related Factors: A Systematic Review Focusing on mCRC;Pharmaceutics;2022-11-15

4. Predicting drug response and toxicity in metastatic colorectal cancer: the role of germline markers;Expert Review of Clinical Pharmacology;2022-06-03

5. Role of Fcγ receptors in HER2-targeted breast cancer therapy;Journal for ImmunoTherapy of Cancer;2022-01